Maeshiro Tatsuji, Arakaki Shingo, Watanabe Takako, Aoyama Hajime, Shiroma Joji, Yamashiro Tsuyoshi, Hirata Tetsuo, Hokama Akira, Kinjo Fukunori, Nakayoshi Tomofumi, Nakayoshi Tomokuni, Mizokami Masashi, Fujita Jiro, Sakugawa Hiroshi
Control and Prevention of Infectious Disease, Department of Medicine and Therapeutics, Faculty of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, Japan.
World J Gastroenterol. 2007 Sep 14;13(34):4560-5. doi: 10.3748/wjg.v13.i34.4560.
To investigate the different impact of genotypes B and C on the development of liver cirrhosis (LC) among different age groups of patients with chronic hepatitis B (CH-B).
We examined the outcome of 121 patients with CH-B, divided by age and genotype. Univariate analyses were used to compare different groups. The Cox proportional hazard model was employed to evaluate factors affecting the development of LC.
In patients < 30 years old, there were no significant predictors for development of LC. However, in patients > or = 30 years old, genotype C was the only significant predictor. In the genotype C group, 8 of 12 patients who progressed to LC were 30-49 years old at initial diagnosis of chronic hepatitis (7 patients were positive for HBeAg). In the genotype B group, 4 of 8 patients who developed LC were > or = 50 years old at initial diagnosis and were HBeAg-negative.
The rate of development of LC was comparable in patients infected with genotypes B and C when CH-B occurred at < 30 years old. However, CH-B patients infected with genotype C showed poor prognosis if they were 30-49 years old and were positive for HBeAg. Age-specific natural course of CH-B should be considered when patients with CH-B are treated with antiviral drugs.
探讨B型和C型基因型对不同年龄组慢性乙型肝炎(CH-B)患者肝硬化(LC)发生发展的不同影响。
我们对121例CH-B患者进行了研究,根据年龄和基因型进行分组。采用单因素分析比较不同组。使用Cox比例风险模型评估影响LC发生发展的因素。
在年龄<30岁的患者中,没有显著的LC发生预测因素。然而,在年龄≥30岁的患者中,C型基因型是唯一显著的预测因素。在C型基因型组中,进展为LC的12例患者中有8例在慢性肝炎初诊时年龄为30-49岁(7例HBeAg阳性)。在B型基因型组中,发生LC的8例患者中有4例在初诊时年龄≥50岁且HBeAg阴性。
当CH-B发生在<30岁时,感染B型和C型基因型的患者LC发生率相当。然而,感染C型基因型的CH-B患者如果年龄在30-49岁且HBeAg阳性,则预后较差。在对CH-B患者进行抗病毒药物治疗时,应考虑CH-B的年龄特异性自然病程。